REFERENCE CODE GDME0186MAR | PUBLICATION DATE OCTOBER 2014
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Aortic Stent Grafts – Global Analysis and Market Forecasts 2 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
Table below provides the key metrics for aortic
stent grafts in the 10 major markets (10MM) (US,
France, Germany, Italy, Spain, UK, Japan, India,
China, and Brazil).
Aortic Stent Grafts, Key Metrics in Major Markets
(2013) Procedure Volume of Abdominal Aortic Aneurysms 82,041
(2013) Procedure Volume of Thoracic Aortic Aneurysms 22,075
2013 Global Market Sales for Aortic Stent Grafts ($m) $1,224m
US $543m
5EU $288m
Asia-Pacific $334m
Brazil $59m
Key Events (2012–2019) Impact
(2014) Cordis Corporation of Johnson & Johnson; the INCRAFT endograft is currently undergoing clinical trials in Europe, Japan, and the US; it is expected to be approved in 2014, 2018, and 2017 in each of the territories, respectively.
↑↑↑
(2014) Strong expectation from Endologix to continue to acquire more market share, thereby slicing into the top three players’ shares.
↑↑↑
(2014) Medtronic to acquire Covidien for $42.9bn, which can result in cuts in their endovascular business.
↑↑
(2014) Strong pipeline of stent grafts with good pipeline products from Asian and Western players. ↑↑
Competitive Assessment
Number of Devices in Marketing Phase 56
2019 Global Market Sales for Aortic Stent Grafts ($m) $1,930m
US $811m
5EU $445m
Asia-Pacific $570m
Brazil $103m
Source: GlobalData; primary research interviews with leading vascular surgeons in 10 markets (US, France, Germany, Italy, Spain, UK, Japan, India, China, and Brazil) 5EU = France, Germany, Italy, Spain, and UK; Asia-Pacific = Japan, India, and China
Sales for Aortic Stent Grafts
The total aortic stent graft sales market in 2013
was estimated to be $1,224m across the 10MM.
By the end of the forecast, the stent graft sales
market will grow to over $1,930m, with a
Compound Annual Growth Rate (CAGR) of 6.7%.
The key drivers for the market in the forecast are:
The growing prevalence of aortic aneurysms
along with the aging population across the
globe with hypertension and obesity.
The growing technological advancement in
minimally invasive procedures and the desire
to eliminate the need for open surgical
procedures for aneurysms.
The major underserved population for
minimally invasive aneurysm treatment in the
emerging markets that is driving the procedural
numbers up.
The unmet need for better clinical outcomes
and long-term studies to reduce the risk of
endoleaks and other complications.
Aortic Stent Grafts – Global Analysis and Market Forecasts 3 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
Figure below depicts the projected growth revenue
for aortic stent grafts in the 10MM from 2013 to
2020.
Aortic Stent Graft Revenue by Major Market (2013–2020)
53.2%
3.1%7.5%
2.0%
2.8%
3.0%
13.0%
3.6%
3.7%5.3%
US
France
Germany
Italy
Spain
UK
Japan
Brazil
China
India
2013$1.2bn
59.8%2.8%
7.6%
1.8%2.2%2.8%
9.6%
3.0%3.1% 4.8%
2020$1.9bn
Source: GlobalData; primary research interviews and surveys with leading vascular surgeons in the 10MM.
The US market consists of the largest portion of
the aortic stent graft market. The US and European
Union (EU) combined formed close to 70% of the
global share in 2013. In the remaining markets,
Japan is the largest with China and Brazil to follow.
India is by far, the smallest market. The EU is
technologically the most advanced market, with the
best availability of fenestrated and custom stent
grafts on the market. The emerging markets see
the most open surgical procedures, but stent use is
restricted due to the cost of the products and
procedures. As training programs for surgeons
increase and product prices decrease, the
emerging markets will present a strong opportunity
for additional revenue for manufacturers. The
overall CAGR across all 10 markets is 6.7%, with
Japan and China representing the biggest growth
opportunities. The growing concerns for
multinational companies reside with the need to
better target the fast-growing markets and the
need to continue to be the leader in development
to combat the threat of rising local manufacturers.
Technological Trends
Within the last twenty years, endovascular
products have dramatically changed with
development relating to improved navigation,
trackability, and flexibility, as well as with the
stability of access, especially through tortuous
anatomy. Imaging technology has had an immense
impact on the treatment rates and detection of
aneurysms as well. The advances in ultrasound
technology have greatly reduced the incidence of
Aortic Stent Grafts – Global Analysis and Market Forecasts 4 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
aneurysm rupture. Within the emerging markets,
these imaging techniques represent an opportunity
for stent graft manufacturers to continue training
programs for better detecting the aneurysms that
are asymptomatic. As a result of better detection,
there can be earlier intervention and fewer open
surgeries, thereby resulting in more stent graft
placement.
The technological developments in endovascular
repair will essentially continue to result in positive
growth. The primary technological drivers include
the development of ultra-low profile systems to
access difficult anatomies and arteries that are
smaller in diameter, especially in the Asian
population. The customized fenestrated products
have provided a major opportunity for physicians to
treat a new patient pool that was only subject to
open repair. As more of these products are
approved in the US and other markets, there can
be a strong case for greater product adoption.
Thoracic endovascular aneurysm repair (TEVAR)
is also an area that is still in its infancy, thus
yielding low procedure numbers. As there is more
development in those product lines and as the
abdominal aortic stent graft product matures, there
can be a strong platform for development in the
abdominal market as well. Generally, there is still
much room for development in endovascular aortic
repair (EVAR) and TEVAR, and as the products
evolve, there will be continued growth in this
market.
Unmet Needs Remain a Challenge
The complications in endovascular repair usually
occur during or immediately after the procedure,
which must be treated immediately through either
interventional or open surgery methods. Endoleaks
are the most common complication and area of
focus; the remaining complications, such as
paraplegia, infection, and limb thrombosis,
amongst others, occur from time to time and
knowledge of them can help enhance future
product design.
Technological challenges also pose an opportunity
for the development of better products with better
clinical outcomes. The availability of lower profile
systems will continue to improve accessibility.
Customized fenestrated stent grafts will allow more
complicated aneurysms to be treated, thereby
enhancing the potential patient pool. Multi-
branched systems will also allow for more tortuous
anatomy to be treated. Finally, addressing the
need for more long-term clinical data will allow
more surgeons to be comfortable implanting stent
grafts, with the assurance of durability in younger
patients.
Key Players in the Aortic Stent Graft Market
At present, the aortic stent grafts market is still
dominated by the top three players: Cook Medical,
Gore Medical, and Medtronic. The products that
are currently approved and on the market are all of
high quality and each have their strengths with
fixation types. The products in development by
Aortic Stent Grafts – Global Analysis and Market Forecasts 5 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
those outside of the top three players are all
innovative in their own way, but a product that will
show superior benefits with a lower or at least
equal cost will be the one to grow the most.
The most talked about emerging player in the
market, based on GlobalData’s key opinion leaders
(KOLs), is Endologix. Endologix has one of the
strongest product pipelines with significantly new
product features and a new approach to treatment
that has the potential to grab a piece of market
share. The next one to three years will determine
the quality of the potential products for Endologix,
based on approval and clinical trials. Globally, the
top 88% of the EVAR market and top 91% in
TEVAR market belongs to the three companies
mentioned earlier. The emerging markets are still
dominated by the top three manufacturers as well,
although the emerging markets also have a
growing number of local players within Brazil,
China, and Japan. India represents the smallest of
the emerging markets, with the potential to grow
upon lower product prices and an increase of
product availability. The ongoing trend in the aortic
stent grafts market is that the leading players will
continue to maintain market share, unless a
disruptive technology in this segment dramatically
changes clinical outcomes.
Aortic Stent Graft Market Future Outlook
The economic downturn has been a source of
continued concern for high priced medical devices
across the global market. The aortic stent grafts
market is not one that is excluded from this trend.
Despite the high product price, physicians still see
a significant benefit in providing endovascular
options versus performing open surgery. As
physician education improves and they have
access to more clinical trial data, the outlook for
the aortic stent grafts looks strong with there being
much room for product improvement.
The market outlook looks strong in the Western
markets, as there is still much room for product
adoption and growth. Regionally, one can expect
slightly different drivers for growth. The US market
is expected to see a significant amount of growth
once there is more availability of the customized
grafts. In some countries, the EU market is still
restricted by cost, thereby making physicians
choose their patients carefully before implantation
of the device. Finally, the markets such as Japan,
China, and Brazil are seeing emerging competition
from smaller firms, which will provide a landscape
for pressuring large firms to reduce product prices.
The aortic stent grafts market is a moderately
growing market at a CAGR of 6.7% globally, with
some individual markets boasting a stronger
CAGR over others. Within the 10MM, it is the
cardiovascular sector that is expected to continue
to grow the most in response to the continual
technological developments and physicians’
acceptance of the products’ successful clinical
performance. The global market is based on, and
will be driven by, the rising prevalence of aortic
aneurysms and the aging population.
Aortic Stent Grafts – Global Analysis and Market Forecasts 6 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
Countries to watch are India and China, but these
markets depend heavily on physician comfort with
the procedure itself and the availability of new
products beyond the major cities and the
distribution networks. GlobalData expects
continued growth in this niche market with the
major deterrent, globally, to be product price once
a product is accepted by a surgeon.
What Do Physicians Think?
Physicians expect the cost of implants to be a
growing concern for practices and hospitals.
“Cost is a major issue all across the board,
specifically here. We try to do everything with the
least cost possible. So, if the grafts are exactly the
same and treat the same problem, then we try to
use the graft that's cheaper.”
Key Opinion Leader
“In an economic downturn, we need to be able to
show that what we do is cost-effective. Many
hospitals, for example, have capped down the
number of procedures that can be done in a year.”
Key Opinion Leader
“I can frankly tell you that if the cost doesn’t come
down, there’s going to be a stagnation. Because
cost is huge now and it’s only done in a few
corporate centers in India; big corporate centers in
India where they have access to everything…
Even the top guys doing the procedure – they also
think the same thing. Even at their level, cost is a
major issue.”
Key Opinion Leader
With regard to the technological trends and
product enhancement expectations, KOLs
speak on what is needed the most today.
“Smaller sheath size, introduction diameter. And
the reason being, is that a major limitation is the
size of the external iliac arteries, disease there, not
allowing you to pass the stent graft up. Lower-
profile delivery devices, which are also in trial.
Actually, they're not on trial. For many companies,
they're brand-new.”
Key Opinion Leader
Physicians discuss government regulations
where reimbursement plays a big part in
choosing to do endovascular repair
procedures.
Aortic Stent Grafts – Global Analysis and Market Forecasts 7 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Executive Summary
“We use the product we think we need. The
expensive price is limiting our activity, of course.
So, we have to choose the product by indication.
So, we cannot use these products. More patients;
[we] have to select the best patients to use on this
because of the price, sure.”
Key Opinion Leader
“They are capitated. I know [in] Canada, they limit
the number of procedures they can do in a year.
I'm allowed to do 20 a year, and after that, they
[patients] all get open [surgery]. So, socialized
medicine does that a lot.”
Key Opinion Leader
Physicians are interested in solid clinical
studies to prove outcomes in products.
“In all honesty, the specific product features don't
matter as much as the trials that show whether a
device is durable or not. Everyone has their little,
‘We have a hook here,’ and other people have the
supra-aortic stents. ‘We have ones with hooks,
ones without hooks. We have screws that go into
the aortic wall.’ The reality is, unless there's some
sort of published data, everything else is just
theoretical. And to me, that doesn't matter.”
Key Opinion Leader
Physicians talk about the shift from open
surgery to endovascular repair.
“In the smaller hospitals where you have older
surgeons who didn't have endovascular training,
those are the ones who need more experience with
the devices than people like myself, who've been
out about four or five years.”
Key Opinion Leader
“[The] endovascular device, we would use that
almost exclusively, except in super young patients.
Patients less than 60, we offer an open operation
just because it's durable. Technically speaking,
you're fixing the problem both ways. It's just that
we know that open will last 30, 40 years. We still
don't know that about endovascular.”
Key Opinion Leader
Aortic Stent Grafts – Global Analysis and Market Forecasts 8 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
1 Table of Contents
1 Table of Contents ....................................................................................................................... 8
1.1 List of Tables .................................................................................................................... 16
1.2 List of Figures ................................................................................................................... 22
2 Introduction ............................................................................................................................... 24
2.1 Catalyst ............................................................................................................................. 25
2.2 Related Reports ................................................................................................................ 26
2.3 Upcoming Related Reports ............................................................................................... 26
3 Industry Overview ..................................................................................................................... 27
3.1 Overview ........................................................................................................................... 27
3.2 Indications ......................................................................................................................... 28
3.2.1 Aortic Abdominal Aneurysm .......................................................................................... 28
3.2.2 Thoracic Aortic Aneurysm ............................................................................................. 29
3.2.3 Aortic Dissection ........................................................................................................... 30
3.3 Clinical Outcomes ............................................................................................................. 31
3.3.1 Lifestyle Changes .......................................................................................................... 32
3.3.2 Medication ..................................................................................................................... 33
3.3.3 Open Surgery ................................................................................................................ 33
3.3.4 Endovascular Repair ..................................................................................................... 34
3.4 Procedure Trends ............................................................................................................. 36
3.4.1 Global............................................................................................................................ 36
3.4.2 US ................................................................................................................................. 39
Aortic Stent Grafts – Global Analysis and Market Forecasts 9 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
3.4.3 EU ................................................................................................................................. 41
3.4.4 Asia-Pacific ................................................................................................................... 43
3.4.5 South America............................................................................................................... 46
3.5 Market Access .................................................................................................................. 48
3.5.1 Adoption ........................................................................................................................ 50
3.5.2 Regulation ..................................................................................................................... 57
3.5.3 Reimbursement ............................................................................................................. 63
3.6 Regulatory Issues/Recalls ................................................................................................. 76
3.6.1 Anaconda Back on the Market in March 2014 after a Voluntary Recall of Anaconda by
Vascutek ...................................................................................................................... 76
3.6.2 Terminated FDA’s Class II Recall of TriVascular’s Ovation Prime in April 2014 ............. 76
3.7 Mergers, Deals, and Acquisitions ...................................................................................... 76
3.7.1 Medtronic Acquires Covidien ......................................................................................... 76
3.7.2 TriVascular Launches $100m Initial Public Offering....................................................... 77
3.7.3 Lombard Medical Pursues US Initial Public Offering ...................................................... 77
3.7.4 TriVascular Raises $40m in Series E Financing ............................................................ 77
3.7.5 LifeTech Scientific Creates Partnership with Medtronic ................................................. 77
3.7.6 LeMaitre Vascular Terminates Distribution Agreement with Endologix .......................... 78
3.7.7 Jotec Enters Licensing Agreement with Hydromer ........................................................ 78
3.7.8 Endologix Public Offering of Notes ................................................................................ 78
3.7.9 Aptus Endosystems Secures Financing ........................................................................ 78
3.7.10 Altura Medical Secures Financing ................................................................................. 78
3.7.11 Endologix Acquires Nellix Endovascular ........................................................................ 79
Aortic Stent Grafts – Global Analysis and Market Forecasts 10 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
3.8 Economic Impact .............................................................................................................. 79
3.8.1 Economic Impact of Aneurysms .................................................................................... 79
3.8.2 Treatment Costs of Aortic Aneurysms ........................................................................... 80
4 Unmet Needs ............................................................................................................................ 82
4.1 Addressing the Complications ........................................................................................... 82
4.1.1 Endoleaks ..................................................................................................................... 82
4.1.2 Ischemic Complications ................................................................................................. 83
4.1.3 Limb Thrombosis ........................................................................................................... 84
4.1.4 Infection ........................................................................................................................ 84
4.1.5 Paraplegia in Thoracic Aortic Aneurysm ........................................................................ 84
4.2 The Seal and Landing Zone .............................................................................................. 85
4.3 Short Neck ........................................................................................................................ 86
4.4 Cost Containment ............................................................................................................. 87
4.5 More Low Profile Systems................................................................................................. 88
4.6 Customized Fenestrated Stent Grafts ............................................................................... 89
4.7 Multi-Branch Stent Grafts .................................................................................................. 90
4.8 Thoracic Endovascular Aneurysm Repair Unmet Needs ................................................... 91
4.9 Long-Term Clinical Data ................................................................................................... 92
5 Market Opportunity Analysis ..................................................................................................... 93
5.1 Emerging Markets ............................................................................................................. 93
5.2 Thoracic Aortic Disease Market ........................................................................................ 94
5.3 Addition of Physician Training Programs ........................................................................... 95
5.4 Disruptive Technologies .................................................................................................... 96
Aortic Stent Grafts – Global Analysis and Market Forecasts 11 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
5.5 Minimally Invasive Trend ................................................................................................... 97
6 Market Drivers, Barriers, and Substitutes .................................................................................. 98
6.1 Driver: Rising Disease Prevalence .................................................................................... 98
6.1.1 Diabetes Mellitus ........................................................................................................... 98
6.1.2 Hypertension ................................................................................................................. 98
6.1.3 Obesity .......................................................................................................................... 99
6.1.4 Tobacco Use ................................................................................................................. 99
6.2 Driver: Aging ..................................................................................................................... 99
6.3 Driver: Imaging................................................................................................................ 100
6.4 Driver: Improved Clinical Outcomes with Endovascular Therapy..................................... 101
6.5 Driver: Time Savings ....................................................................................................... 102
6.6 Driver: Patient Demand and Awareness.......................................................................... 102
6.7 Driver: Technological Developments ............................................................................... 103
6.7.1 Custom Branched and Fenestrated Stent Grafts ......................................................... 103
6.7.2 Low Profile Delivery Systems ...................................................................................... 104
6.8 Driver: Rising Competition and Innovation ...................................................................... 105
6.9 Barrier: Availability of Venture Capital ............................................................................. 105
6.10 Barrier: Burden of Rising Regulation ............................................................................... 106
6.11 Barrier: High Treatment Cost .......................................................................................... 107
6.12 Barrier: Proving Long-Term Efficacy ............................................................................... 109
6.13 Barrier: High Radiation Dosages with Excessive Imaging ............................................... 109
6.14 Surgical Limitations ......................................................................................................... 110
6.15 Barrier: Medical Device Excise Tax ................................................................................. 110
Aortic Stent Grafts – Global Analysis and Market Forecasts 12 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
6.16 Substitute: Open Surgery ................................................................................................ 111
6.17 Substitute: Chimney Technique versus Fenestrated Grafts ............................................. 112
7 Competitive Assessment ........................................................................................................ 114
7.1 Overview ......................................................................................................................... 114
7.2 Key Marketed Products ................................................................................................... 114
7.2.1 Endovascular Aneurysm Repair and Thoracic Endovascular Aneurysm Repair Products
................................................................................................................................... 114
8 Pipeline Assessment............................................................................................................... 125
8.1 Overview ......................................................................................................................... 125
8.2 Product Profiles ............................................................................................................... 125
8.2.1 Altura Medical Endograft ............................................................................................. 125
8.2.2 Cordis INCRAFT ......................................................................................................... 126
8.2.3 EndoSpan Horizon ...................................................................................................... 127
8.2.4 EndoSpan Nexus ........................................................................................................ 128
8.2.5 MicroPort Scientific Castor Branched Stent Graft System ........................................... 129
8.2.6 BiFlow Medical Novel Side-Branch Stent .................................................................... 130
8.2.7 Endoluminal Sciences Endograft Mechanism .............................................................. 131
8.2.8 Medtronic Valiant Mona LSA Stent Graft System ........................................................ 132
8.2.9 Endologix Ventana Fenestrated Stent Graft ................................................................ 132
9 Clinical Trials to Watch ........................................................................................................... 134
9.1 Overview ......................................................................................................................... 134
9.2 Altura Medical ................................................................................................................. 134
9.3 Cook Medical .................................................................................................................. 135
Aortic Stent Grafts – Global Analysis and Market Forecasts 13 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
9.4 Gore Medical .................................................................................................................. 137
9.5 Terumo Corporation ........................................................................................................ 138
9.6 Endologix ........................................................................................................................ 138
9.7 TriVascular ...................................................................................................................... 139
9.8 Bolton Medical ................................................................................................................ 140
9.9 Medtronic ........................................................................................................................ 141
9.10 Cordis Corporation .......................................................................................................... 143
10 Current and Future Players ..................................................................................................... 144
10.1 Overview ......................................................................................................................... 144
10.2 Trends in Corporate Strategy .......................................................................................... 144
10.3 Company Profiles ............................................................................................................ 145
10.3.1 Cook Medical .............................................................................................................. 145
10.3.2 Endologix .................................................................................................................... 148
10.3.3 Gore Medical ............................................................................................................... 151
10.3.4 Medtronic .................................................................................................................... 153
10.3.5 Terumo Corporation .................................................................................................... 156
10.3.6 Altura Medical ............................................................................................................. 158
10.3.7 Aptus Endosystems..................................................................................................... 159
10.3.8 Bolton Medical............................................................................................................. 161
10.3.9 Braile Biomédica ......................................................................................................... 163
10.3.10 B. Braun ...................................................................................................................... 166
10.3.11 Cardiatis ...................................................................................................................... 167
10.3.12 LeMaitre Vascular ....................................................................................................... 169
Aortic Stent Grafts – Global Analysis and Market Forecasts 14 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
10.3.13 Lifetech Scientific ........................................................................................................ 171
10.3.14 Getinge Group............................................................................................................. 173
10.3.15 Grikin Advanced Materials........................................................................................... 176
10.3.16 Johnson & Johnson’s Cordis Corporation .................................................................... 177
10.3.17 Jotec ........................................................................................................................... 179
10.3.18 Lombard Medical ......................................................................................................... 181
10.3.19 MicroPort Scientific Corporation .................................................................................. 182
10.3.20 Nano Endoluminal ....................................................................................................... 185
10.3.21 TriVascular .................................................................................................................. 187
10.3.22 Weike Medical Apparatus and Instrument ................................................................... 190
10.3.23 YTH Biological Material Scitech................................................................................... 190
11 Market Outlook ....................................................................................................................... 191
11.1 Company Market Share .................................................................................................. 191
11.1.1 Global Market Share ................................................................................................... 191
11.1.2 US Market Share ......................................................................................................... 194
11.1.3 EU Market Share ......................................................................................................... 196
11.2 By Market Segment......................................................................................................... 198
11.2.1 Overview ..................................................................................................................... 198
11.2.2 Endovascular Aneurysm Repair .................................................................................. 199
11.2.3 Thoracic Endovascular Aneurysm Repair .................................................................... 200
11.3 By Geography ................................................................................................................. 201
11.3.1 Global Overview .......................................................................................................... 201
11.3.2 US ............................................................................................................................... 205
Aortic Stent Grafts – Global Analysis and Market Forecasts 15 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
11.3.3 EU ............................................................................................................................... 207
11.3.4 Asia-Pacific ................................................................................................................. 219
11.3.5 South America............................................................................................................. 228
12 Appendix................................................................................................................................. 231
12.1 Bibliography .................................................................................................................... 231
12.2 Abbreviations .................................................................................................................. 247
12.3 Research Methodology ................................................................................................... 251
12.3.1 Overview ..................................................................................................................... 251
12.3.2 Coverage .................................................................................................................... 251
12.3.3 Secondary Research ................................................................................................... 251
12.4 Physicians and Specialists Included in this Study ........................................................... 253
12.4.1 Christopher Abularrage, MD, FACS ............................................................................ 253
12.4.2 Gaspar Mestres Alomar, MD ....................................................................................... 253
12.4.3 Enio Buffolo, MD, PhD ................................................................................................ 253
12.4.4 Ludovic Canaud, MD, PhD .......................................................................................... 253
12.4.5 Holger Eggebrecht, MD ............................................................................................... 253
12.4.6 Daisuke Fukui, MD, PhD ............................................................................................. 253
12.4.7 Germano Melissano, MD ............................................................................................. 253
12.4.8 Dr. Raghuram Sekhar MS, FRCS (Edinburgh), FRCS (Glasgow) ................................ 253
12.4.9 Ferdinand Serracino-Inglott, MD, MSc, FRCSI, FRCS (Gen Surg), DIC ...................... 254
12.4.10 Jiang Xiong, MD, PhD ................................................................................................. 254
12.5 Primary Research ........................................................................................................... 255
12.5.1 Primary Research – Key Opinion Leader Interviews.................................................... 255
Aortic Stent Grafts – Global Analysis and Market Forecasts 16 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
12.5.2 Primary Research – Physician and Industry Interviews ............................................... 255
12.5.3 Expert Panel Validation ............................................................................................... 256
12.6 Forecasting Methodology ................................................................................................ 257
12.7 About the Authors ........................................................................................................... 258
12.7.1 Analysts ...................................................................................................................... 258
12.7.2 Global Head of Healthcare .......................................................................................... 259
12.8 About MediPoint .............................................................................................................. 260
12.9 About GlobalData ............................................................................................................ 260
12.10 Disclaimer ....................................................................................................................... 260
1.1 List of Tables
Table 1: Summary of Indications, Symptoms, and Treatments ....................................................................... 28
Table 2: Thoracic Aortic Aneurysm Types ...................................................................................................... 30
Table 3: Medications for Reducing Risk of Aneurysm Growth and Rupture .................................................... 33
Table 4: Advantages and Disadvantages of Open Repair versus Endovascular Repair .................................. 35
Table 5: Global Abdominal Aortic Stent Grafts Procedure Volume, 2011–2020 .............................................. 36
Table 6: Global Thoracic Aortic Stent Grafts Procedure Volume, 2011–2020 ................................................ 38
Table 7: Group Purchasing Organizations in the US and EU .......................................................................... 56
Table 8: Regulatory Differences between the US and EU............................................................................... 58
Table 9: Medicare National Average of Inpatient Hospital Payment for EVAR and TEVAR, 2013–2014 .......... 65
Table 10: Medicare Coding Guide for EVAR and TEVAR, 2014 ..................................................................... 65
Table 11: Direct and Indirect Costs of Open Surgery and Endovascular Repair .............................................. 81
Table 12: Comparison Costs and Other Variables for Treating AAA By Open Repair and Stent Grafts in 2012
($US) .......................................................................................................................................... 81
Aortic Stent Grafts – Global Analysis and Market Forecasts 17 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Table 13: Endoleak Types ............................................................................................................................. 82
Table 14: Zenith Family Marketed Products ................................................................................................. 116
Table 15: Zenith AAA SWOT ....................................................................................................................... 116
Table 16: Zenith TAA SWOT ....................................................................................................................... 117
Table 17: Endologix’s Marketed Products .................................................................................................... 118
Table 18: AFX Endovascular SWOT ............................................................................................................ 118
Table 19: IntuiTrak Powerlink System SWOT ............................................................................................... 118
Table 20: Gore Medical’s Marketed Products ............................................................................................... 120
Table 21: Gore AAA Product SWOT ............................................................................................................ 120
Table 22: Gore TAA Product SWOT ............................................................................................................ 121
Table 23: Medtronic’s Marketed Products .................................................................................................... 122
Table 24: Medtronic AAA Product SWOT ..................................................................................................... 123
Table 25: Medtronic TAA Product SWOT ..................................................................................................... 123
Table 26: Terumo Corporation Marketed Products ....................................................................................... 124
able 27: Terumo Corporation AAA Product SWOT ....................................................................................... 124
Table 28: SWOT Analysis – Altura Medical Endograft .................................................................................. 126
Table 29: SWOT Analysis – Cordis INCRAFT .............................................................................................. 127
Table 30: SWOT Analysis – EndoSpan Horizon ........................................................................................... 128
Table 31: SWOT Analysis – EndoSpan Nexus ............................................................................................. 129
Table 32: SWOT Analysis – MicroPort Scientific Castor Branched Stent Graft System ................................. 130
Table 33: SWOT Analysis – BiFlow Medical Novel Side-Branch Stent .......................................................... 131
Table 34: SWOT Analysis – Endoluminal Sciences Endograft Mechanism ................................................... 131
Table 35: SWOT Analysis – Medtronic Valiant Mona LSA Stent Graft .......................................................... 132
Table 36: SWOT Analysis – Endologix Ventana Fenestrated Stent Graft...................................................... 133
Aortic Stent Grafts – Global Analysis and Market Forecasts 18 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Table 37: Major Clinical Trials of Altura Medical’s Aortic Stent Grafts ........................................................... 135
Table 38: Major Clinical Trials of Cook Medical’s Aortic Stent Grafts ............................................................ 136
Table 39: Major Clinical Trials of Gore Medical’s Aortic Stent Grafts............................................................. 137
Table 40: Major Clinical Trials of Terumo’s Aortic Stent Grafts ..................................................................... 138
Table 41: Major Clinical Trials of Endologix’s Aortic Stent Grafts .................................................................. 139
Table 42: Major Clinical Trials of TriVascular’s Aortic Stent Grafts ................................................................ 140
Table 43: Major Clinical Trials of Bolton Medical’s Aortic Stent Grafts .......................................................... 141
Table 44: Major Clinical Trials of Medtronic’s Aortic Stent Grafts .................................................................. 142
Table 45: Major Clinical Trials of Cordis’ Aortic Stent Grafts ......................................................................... 143
Table 46: Company Profile – Cook Medical.................................................................................................. 146
Table 47: Cook Medical Marketed Products ................................................................................................. 147
Table 48: SWOT Analysis – Cook Medical ................................................................................................... 148
Table 49: Company Profile – Endologix Inc. ................................................................................................. 149
Table 50: Endologix Marketed Products ....................................................................................................... 150
Table 51: Endologix Pipeline Products ......................................................................................................... 150
Table 52: SWOT Analysis – Endologix Inc. .................................................................................................. 150
Table 53: Company Profile – Gore Medical .................................................................................................. 151
Table 54: Gore Medical Marketed Products ................................................................................................. 152
Table 55: SWOT Analysis – Gore Medical ................................................................................................... 153
Table 56: Company Profile – Medtronic ....................................................................................................... 154
Table 57: Medtronic Marketed Products ....................................................................................................... 155
Table 58: SWOT Analysis – Medtronic ......................................................................................................... 155
Table 59: Company Profile – Terumo Corporation........................................................................................ 156
Table 60:Terumo Corporation Marketed Products ........................................................................................ 157
Aortic Stent Grafts – Global Analysis and Market Forecasts 19 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Table 61: SWOT Analysis – Terumo Corporation ......................................................................................... 158
Table 62: Company Profile – Altura Medical Inc. .......................................................................................... 158
Table 63: Altura Medical Inc. Marketed Products ......................................................................................... 159
Table 64: SWOT Analysis – Altura Medical Inc. ........................................................................................... 159
Table 65: Company Profile – Aptus Endosystems, Inc. ................................................................................ 160
Table 66: Aptus Endosystems Inc. Marketed Products ................................................................................. 161
Table 67: SWOT Analysis – Aptus Endosystems Inc. ................................................................................... 161
Table 68: Company Profile – Bolton Medical ................................................................................................ 162
Table 69: Bolton Medical Marketed Products ............................................................................................... 163
Table 70: SWOT Analysis – Bolton Medical ................................................................................................. 163
Table 71: Company Profile – Braile Biomédica............................................................................................. 164
Table 72: Braile Biomédica Marketed Products ............................................................................................ 165
Table 73: SWOT Analysis – Braile Biomédica .............................................................................................. 165
Table 74: Company Profile – B. Braun ......................................................................................................... 166
Table 75: B. Braun Marketed Products ........................................................................................................ 167
Table 76: SWOT Analysis – B. Braun .......................................................................................................... 167
Table 77: Company Profile – Cardiatis ......................................................................................................... 168
Table 78: Cardiatis Marketed Products ........................................................................................................ 168
Table 79: SWOT Analysis – Cardiatis .......................................................................................................... 169
Table 80: Company Profile – LeMaitre Vascular ........................................................................................... 170
Table 81: LeMaitre Vascular Medical Marketed Products ............................................................................. 170
Table 82: SWOT Analysis – LeMaitre Vascular ............................................................................................ 171
Table 83: Company Profile – Lifetech Scientific............................................................................................ 172
Table 84: Lifetech Scientific Marketed Products ........................................................................................... 172
Aortic Stent Grafts – Global Analysis and Market Forecasts 20 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Table 85: SWOT Analysis – Lifetech Scientific ............................................................................................. 173
Table 86: Company Profile – Getinge Group ................................................................................................ 174
Table 87: Getinge Group Marketed Products ............................................................................................... 175
Table 88: SWOT Analysis – Getinge Group ................................................................................................. 175
Table 89: Company Profile – Grikin Advanced Materials .............................................................................. 176
Table 90: Grikin Advanced Materials Marketed Products ............................................................................. 176
Table 91: SWOT Analysis – Grikin Advanced Materials ............................................................................... 177
Table 92: Company Profile – Johnson & Johnson Cordis Corporation .......................................................... 177
Table 93: Cordis Corporation’s Pipeline Product .......................................................................................... 178
Table 94: SWOT Analysis – Cordis Corporation ........................................................................................... 178
Table 95: Company Profile – Jotec .............................................................................................................. 179
Table 96: Jotec’s Marketed Products ........................................................................................................... 180
Table 97: SWOT Analysis – Jotec ................................................................................................................ 180
Table 98: Company Profile – Lombard Medical ............................................................................................ 181
Table 99: Lombard Medical Marketed Products ........................................................................................... 182
Table 100: SWOT Analysis – Lombard Medical ........................................................................................... 182
Table 101: Company Profile – Microport Scientific Corporation .................................................................... 183
Table 102: MicroPort Scientific Marketed Products ...................................................................................... 184
Table 103: SWOT Analysis – MicroPort Scientific ........................................................................................ 185
Table 104: Company Profile – Nano Endoluminal ........................................................................................ 186
Table 105: Nano Endoluminal Medical Marketed Products ........................................................................... 186
Table 106: SWOT Analysis – Nano Endoluminal .......................................................................................... 187
Table 107: Company Profile – TriVascular ................................................................................................... 188
Table 108: TriVascular Marketed Products................................................................................................... 189
Aortic Stent Grafts – Global Analysis and Market Forecasts 21 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Table 109: SWOT Analysis – TriVascular .................................................................................................... 189
Table 110: Global Aortic Stent Grafts Sales ($m) Forecast, by Segment, 2011–2020 ................................... 198
Table 111: Global Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011–2020 ............................................ 199
Table 112: Global Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011–2020 .......................................... 201
Table 113: Aortic Stent Grafts Sales ($m) for the Major Markets, 2011–2020 ............................................... 202
Table 114: Aortic Stent Grafts Sales ($m) for the US, 2011–2020 ................................................................ 205
Table 115: Aortic Stent Grafts Sales ($m) Forecast for the 5EU, 2011–2020 ................................................ 208
Table 116: Aortic Stent Grafts Sales ($m) Forecast for France, 2011–2020.................................................. 210
Table 117: Aortic Stent Grafts Sales ($m) Forecast for Germany, 2011–2020 .............................................. 212
Table 118: Aortic Stent Grafts Sales ($m) Forecast for Italy, 2011–2020 ...................................................... 215
Table 119: Aortic Stent Grafts ($m) Forecast for Spain, 2011–2020 ............................................................. 217
Table 120: Aortic Stent Grafts Sales ($m) Forecast for the UK, 2011–2020 .................................................. 219
Table 121: Aortic Stent Grafts Sales ($m) Forecast for the APAC Region, 2011–2020 ................................. 220
Table 122: Aortic Stent Grafts Sales ($m) Forecast for Japan, 2011–2020 ................................................... 223
Table 123: Aortic Stent Grafts Sales ($m) Forecast for China, 2011–2020 ................................................... 224
Table 124: Aortic Stent Grafts Sales ($m) Forecast for India, 2011–2020 ..................................................... 227
Table 125: Aortic Stent Grafts Sales ($m) Forecast for Brazil, 2011–2020 .................................................... 230
Aortic Stent Grafts – Global Analysis and Market Forecasts 22 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
1.2 List of Figures
Figure 1: Treatment Methodology Markov Model ........................................................................................... 32
Figure 2: Aortic Stent Graft Product Image ..................................................................................................... 35
Figure 3: Global Abdominal Aortic Stent Grafts Procedure Volume, 2011–2020 ............................................. 37
Figure 4: Global Thoracic Aortic Stent Grafts Procedure Volume, 2011–2020 ................................................ 38
Figure 5: US Abdominal Aortic Stent Grafts Procedure Volume, 2011–2020 .................................................. 40
Figure 6: US Thoracic Aortic Stent Grafts Procedure Volume, 2011–2020 ..................................................... 41
Figure 7: EU Abdominal Aortic Stent Grafts Procedure Volume, 2011–2020 .................................................. 42
Figure 8: EU Thoracic Aortic Stent Grafts Procedure Volume, 2011–2020 ..................................................... 43
Figure 9: APAC Abdominal Aortic Stent Grafts Procedure Volume, 2011–2020 .............................................. 45
Figure 10: APAC Thoracic Aortic Stent Grafts Procedure Volume, 2011–2020 ............................................... 46
Figure 11: South America Abdominal Aortic Stent Grafts Procedure Volume, 2011–2020 .............................. 47
Figure 12: South America Thoracic Aortic Stent Grafts Procedure Volume, 2011–2020.................................. 48
Figure 13: Global Market Share for EVAR, 2013 .......................................................................................... 193
Figure 14: Global Market Share for TEVAR, 2013 ........................................................................................ 194
Figure 15: US Market Share for EVAR, 2013 ............................................................................................... 195
Figure 16: US Market Share for TEVAR, 2013 ............................................................................................. 196
Figure 17: EU Market Share for EVAR, 2013 ............................................................................................... 197
Figure 18: EU Market Share for TEVAR, 2013 ............................................................................................. 197
Figure 19: Global Aortic Stent Grafts Sales ($m) Forecast, by Segment, 2011–2020.................................... 199
Figure 20: Global Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011–2020 ............................................. 200
Figure 21: Global Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011–2020........................................... 201
Figure 22: Aortic Stent Grafts Sales ($m) for the Major Markets, 2011–2020 ................................................ 203
Figure 23: Aortic Stent Grafts by Major Market, 2013 and 2020 .................................................................... 204
Aortic Stent Grafts – Global Analysis and Market Forecasts 23 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Table of Contents
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Figure 24: US Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 ........................................................ 206
Figure 25: 5EU Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 ...................................................... 209
Figure 26: France Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 .................................................. 211
Figure 27: Germany Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 ............................................... 213
Figure 28: Italy Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 ....................................................... 215
Figure 29: Spain Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 .................................................... 217
Figure 30: UK Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 ........................................................ 219
Figure 31: APAC Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 .................................................... 221
Figure 32: Japan Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 .................................................... 223
Figure 33: China Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 .................................................... 225
Figure 34: India Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020...................................................... 228
Figure 35: Brazil Sales ($m) Forecast for Aortic Stent Grafts, 2011–2020 .................................................... 230
Figure 36: Aortic Stent Graft Primary Research, Supply and Demand-Side Interviews.................................. 256
Aortic Stent Grafts – Global Analysis and Market Forecasts 24 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Introduction
2 Introduction
Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known
as an aneurysm. The stent grafts are designed to seal tightly with the patient’s native artery above
and below the aneurysm, and are used to treat abdominal aortic aneurysms (AAAs) as well as
thoracic aortic aneurysms (TAAs). Aortic aneurysms, as opposed to aneurysms found elsewhere in
the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can
be fatal unless treated rapidly by an experienced emergency medical team. Since their introduction
in patients in 1991, aortic stent graft devices have gained wide acceptance and availability, with
their adoption fueled in great part by advances in stent-graft design and by a variety of devices for
various anatomic features. Over time, these devices have gained traction for use in patients with
ruptured aneurysms because they are minimally invasive and have shorter recovery times.
Based on GlobalData’s key opinion leader (KOL) research, in the more mature Western markets,
about 80% of surgical treatments for aneurysms are treated through endovascular therapy. The
remaining market is treated by open surgical options. This surgical rate is reduced further in the
emerging nations, due to the high product cost. While endovascular therapy has its clear benefits,
there are strong arguments still being made both clinically, and from a cost perspective, to continue
doing open surgery. Overall, this minimally invasive endovascular technique saves hospitalization
costs in the short run while it continues to bring in revenue for hospitals and practices, as several
more of these cases can be scheduled in a day, with shorter surgical times.
From a clinical standpoint, there are a multitude of clinical trials in progress as the stent grafts and
their delivery systems are trending towards lower and lower profile systems, thereby allowing the
products to be used on a wider patient population that previously, was treatable only through open
techniques. Overall, GlobalData expects the procedural data to continue to grow across the 10
major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, India, China, and Brazil),
with the greatest opportunity being in the emerging nations.
This report focuses on the aortic stent graft implant market for abdominal and TAAs. The
abdominal aortic market comprises about 80–90% of the market, with the niche market being the
thoracic one. The thoracic aneurysm repair market is still a young market where there is a strong
pipeline of products from both the large manufacturers and small emerging players. For most
manufacturers, following the successful launch of an AAA product, the thoracic stent graft segment
presents the opportunity with the most unmet needs for pursuit.
Aortic Stent Grafts – Global Analysis and Market Forecasts 25 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Introduction
The 10MM are covered and forecast in this report, which provides the unmet needs, future
adoption, and Compound Annual Growth Rates (CAGRs) in both the abdominal stent graft and
thoracic stent graft markets. GlobalData’s analysis demonstrates this market to be a young and
growing market, subject to rapid technological development and with much room for product
adoption.
2.1 Catalyst
Increasing the applicability of aortic stent grafts to patients with difficult anatomic features will
likewise require improvements as well as innovation in device design. Currently, the three most
common anatomic reasons for exclusion from the endovascular repair of AAAs are inappropriate
aortic (proximal) neck access, iliac artery aneurysms, and inadequate iliac access. Researchers
have noted that the next frontier for aortic stent grafts will be the continued adoption and
development of endografts that are capable of treating various types of aortic aneurysms for a
number of different patient anatomies. Further, in order to avoid follow-up on patients with
implanted devices, future aortic stent graft products will have increased durability, refined designs
to allow for treatment in the most difficult anatomies, and advanced abilities to treat aneurysms
involving the renal and visceral segments of the aorta.
There are significant opportunities remaining for companies that can develop slimmer devices with
reduced sheath diameter, improve the fixation of grafts, or add additional features including
branches or fenestrated necks. Currently, some of the most frequently encountered barriers for
aortic stent graft use consist of an inadequate or inappropriate proximal neck anatomy and an
inadequate caliber of iliofemoral access vessels. As such, the ability of devices to accommodate
patients with difficult necks or treacherous access vessels is important. That said, novel bifurcated
endografts along with the development of widely available branched and fenestrated grafts are
expected to address these barriers, thereby improving upon the already remarkable clinical
success of this procedure. This report looks at the current aortic stent grafts market for
cardiovascular disease and evaluates the adoption and opportunities for this technology in the
10MM. Globally, this market is expected to rise from $1.3 billion in 2014 to $1.9 billion in 2020, at a
CAGR of 6.7%.
Currently, some of the most frequently encountered barriers for aortic stent graft use consist of an inadequate or inappropriate proximal neck anatomy and an inadequate caliber of iliofemoral access vessels.
Aortic Stent Grafts – Global Analysis and Market Forecasts 26 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
Introduction
2.2 Related Reports
GlobalData (2012). Bioabsorbable Stents – Global Market Analysis and Forecasts, December
2012, GDME0164MAR
GlobalData (2012). Peripheral Vascular Stents – Global Market Analysis and Forecasts, April
2012, GDME0168MAR
GlobalData (2013). Drug Eluting Balloons – Global Market Analysis and Forecasts, September
2013, GDME0179MAR
GlobalData (2014). Neurovascular Interventions – Global Market Analysis and Forecasts April
2014, GDME0194MAR
2.3 Upcoming Related Reports
GlobalData (2014). Coronary Stents – Global Market Analysis and Forecast, to be published
Aortic Stent Grafts – Global Analysis and Market Forecasts 260 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form.
Appendix
AORTIC STENT GRAFTS – GLOBAL ANALYSIS AND MARKET FORECASTS
12.8 About MediPoint
MediPoint is the flagship product for GlobalData’s Medical team. Each MediPoint report is built
from the ground up by our team of healthcare analysts in the US and UK. Each report includes
input from experienced physicians and leading Key Opinion Leaders (KOLs). Running throughout
each report in the series are, “What Do Physicians Think” quotes, which provide a unique insight
into how healthcare professionals are reacting to events within the industry, and what their
responses could mean for industry strategists. The MediPoint series also features Excel-based
forecast models that are robust, fully transparent, and easy to navigate. Moreover, our models
support the data that is presented in the reports, and the complete methodology is outlined in the
report and the model.
12.9 About GlobalData
GlobalData is a leading global provider of business intelligence in the healthcare industry.
GlobalData provides its clients with up-to-date information and analysis on the latest developments
in drug research, disease analysis, and clinical research and development. Our integrated business
intelligence solutions include a range of interactive online databases, analytical tools, reports, and
forecasts. Our analysis is supported by a 24/7 client support and analyst team.
GlobalData has offices in New York, San Francisco, Boston, London, India, Korea, Japan,
Singapore, and Australia.
12.10 Disclaimer
All Rights Reserved.
No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any
form by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior
permission of the publisher, GlobalData.